RIGEL PHARMACEUTICALS INC
For the period ended Dec 31, 2025. Filed Mar 3, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 3, 2026
RIGL$43.91+4.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets
(In thousands, except share and per share amounts)
| As of December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $40,580 | $56,746 |
| Short-term investments | 114,375 | 20,575 |
| Accounts receivable, net | 51,763 | 41,615 |
| Inventories | 11,506 | 6,002 |
| Prepaid and other current assets | 21,942 | 10,165 |
| Total current assets | 240,166 | 135,103 |
| Intangible assets, net | 24,748 | 27,100 |
| Deferred income tax asset | 245,852 | — |
| Operating lease right-of-use assets | 920 | 246 |
| Other assets | 1,908 | 1,527 |
| Total assets | $513,594 | $163,976 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $7,191 | $3,339 |
| Accrued compensation | 11,914 | 10,139 |
| Accrued research and development | 5,524 | 4,073 |
| Acquisition related liabilities | 5,000 | — |
| Revenue reserves and refund liability | 27,716 | 26,440 |
| Loans payable, net, current portion | 29,812 | 7,272 |
| Other current liabilities | 11,466 | 11,751 |
| Lease liabilities, current portion | 614 | 285 |
| Total current liabilities | 99,237 | 63,299 |
| Acquisition-related liabilities | — | 5,000 |
| Long-term portion of lease liabilities | 395 | — |
| Long-term portion of loans payable, net | 22,482 | 52,408 |
| Other long-term liabilities | — | 39,981 |
| Total liabilities | 122,114 | 160,688 |
| Commitments | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value; 10,000,000 shares authorized; none issued and outstanding as of December 31, 2025 and 2024 | — | — |
| Common stock, $0.001 par value; 400,000,000 shares authorized; 18,310,934 and 17,710,216 shares issued and outstanding as of December 31, 2025 and 2024, respectively | 18 | 18 |
| Additional paid-in capital | 1,414,322 | 1,393,325 |
| Accumulated other comprehensive income | 181 | 10 |
| Accumulated deficit | (1,023,041) | (1,390,065) |
| Total stockholders’ equity | 391,480 | 3,288 |
| Total liabilities and stockholders’ equity | $513,594 | $163,976 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.